Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Relmada Therapeutics (RLMD) Cost of Revenue (2024 - 2026)

Relmada Therapeutics has reported Cost of Revenue over the past 3 years, most recently at $685.0 for Q1 2014.

  • Quarterly Cost of Revenue fell 63.25% to $685.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was $2693.0 through Feb 2014, down 46.18% year-over-year, with the annual reading at $3.5 million for FY2025, 125.33% up from the prior year.
  • Cost of Revenue was $685.0 for Q1 2014 at Relmada Therapeutics, down from $1686.0 in the prior quarter.
  • Over five years, Cost of Revenue peaked at $1864.0 in Q1 2013 and troughed at $292.0 in Q2 2012.
  • The 3-year median for Cost of Revenue is $998.0 (2012), against an average of $1099.6.
  • Year-over-year, Cost of Revenue increased 10.27% in 2013 and then crashed 63.25% in 2014.
  • A 3-year view of Cost of Revenue shows it stood at $1850.0 in 2012, then fell by 8.86% to $1686.0 in 2013, then tumbled by 59.37% to $685.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Cost of Revenue are $685.0 (Q1 2014), $1686.0 (Q4 2013), and $322.0 (Q2 2013).